Effective control of infection-associated hemophagocytic syndrome with chloroquine.
A retrospective study was carried out to evaluate the efficacy and the side effects of chloroquine in the treatment of 27 patients with infection-associated hemophagocytic syndrome and compared these with patients described in the literature. All patients received 20 to 25 mg/kg chloroquine per day orally for 7 days (a single course). Twenty-one patients who received one or two courses of treatment showed excellent responses; two patients showed no response to treatment. Two other patients refused to receive treatment with chloroquine. The response rate was 85.2%. Side effects were minimal and well tolerated. No relapses occurred in 19 patients. These results suggest that effective control of disease in some patients with infection-associated hemophagocytic syndrome can be achieved with chloroquine.
Gong
Xin-shun
XS
Tianjin Children's Hospital, Tianjin, China.
D000293:Adolescent; D000962:Antimalarials / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002738:Chloroquine / Q000627:therapeutic use*; D005260:Female; D005334:Fever / Q000209:etiology; D015616:Histiocytosis, Non-Langerhans-Cell / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D007223:Infant; D008297:Male; D012189:Retrospective Studies
D000962:Antimalarials; D002738:Chloroquine